Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin.

ABSTRACT: The epidermal growth factor receptor 2, ERBB2, is a well-validated target for cancer diagnostics and therapy. Recent studies suggest that the over-expression of this receptor in various cancers might also be exploited for antibody-based payload delivery, e.g. antibody drug conjugates. In such strategies, the full-length antibody format is probably not required for therapeutic effect and smaller tumor-specific affinity proteins might be an alternative. However, small proteins and peptides generally suffer from fast excretion through the kidneys, and thereby require frequent administration in order to maintain a therapeutic concentration. In an attempt aimed at combining ERBB2-targeting with antibody-like pharmacokinetic properties in a small protein format, we have engineered bispecific ERB

SUBMITTER: Nilvebrant J 

PROVIDER: S-EPMC4121139 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature